Evidence map›Paper›PMID 38455668›Full record

ArticlePathogens & immunity2023

Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?

Justin Harper, Michael R Betts, Mathias Lichterfeld, Michaela Müller-Trutwin, David Margolis, Katharine J Bar, Jonathan Z Li, Joseph M McCune, Sharon R Lewin, Deanna Kulpa and 3 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Pathogens & immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 3 countries.

Justin HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia.
Michael R BettsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.
Michaela Müller-TrutwinHIV Inflammation and Persistence Unit, Institut Pasteur, Université Paris-Cité, Paris, France.
David MargolisDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina.
Katharine J BarCenter for AIDS Research, University of Pennsylvania, Philadelphia, Pennsylvania.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Joseph M McCuneHIV Frontiers, Global Health Accelerator, Bill & Melinda Gates Foundation.
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Deanna KulpaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia.
Dázon Dixon DialloSisterLove, Inc., Atlanta, Georgia.
Michael M LedermanDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, Ohio.
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia.
Emory University · USBill & Melinda Gates Foundation · USBrigham and Women's Hospital · USCase Western Reserve University · USPenn Center for AIDS Research · USRagon Institute of MGH, MIT and Harvard · USThe Royal Melbourne Hospital · AUUniversité Paris Cité · FRUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1U01AI169767 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Katharine June Bar, Rebecca Marie Lynch · 2022 to 2026
$8.4M
Characterizing the viral and host effector mechanisms that govern HIV-1 reboundR01AI162646 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, HAHN, BEATRICE H · 2021 to 2025
$4.1M
NIAID NIH HHS R01 AI162646NIAID NIH HHS U01 AI169767NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132
6 · The paper itself

Abstract

Once a death sentence, HIV is now considered a manageable chronic disease due to the development of antiretroviral therapy (ART) regimens with minimal toxicity and a high barrier for genetic resistance. While highly effective in arresting AIDS progression and rendering the virus untransmissible in people living with HIV (PLWH) with undetectable viremia (U=U) [1, 2]), ART alone is incapable of eradicating the "reservoir" of resting, latently infected CD4

Indexed as

ARTHIVHIV controlHIV curepersistencereservoirSIV

Identifiers

PMID38455668
PMCPMC10919397
OpenAlexW4392349284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.